NovoCure (NVCR) News Today $30.80 +0.40 (+1.32%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NovoCure (NASDAQ:NVCR) Sets New 52-Week High - Should You Buy?NovoCure (NASDAQ:NVCR) Sets New 12-Month High - Time to Buy?December 18 at 3:33 PM | marketbeat.comNovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst SaysDecember 15, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Shares Gap Up Following Analyst UpgradeDecember 15, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Shares Gap Up After Analyst UpgradeNovoCure (NASDAQ:NVCR) Shares Gap Up After Analyst UpgradeDecember 13, 2024 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for NovoCure (NASDAQ:NVCR) StockPiper Sandler increased their price target on NovoCure from $28.00 to $42.00 and gave the company an "overweight" rating in a research report on Friday.December 13, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsDecember 11, 2024 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating oDecember 11, 2024 | marketbeat.com47,034 Shares in NovoCure Limited (NASDAQ:NVCR) Acquired by Weiss Asset Management LPWeiss Asset Management LP purchased a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 47,034 shares of the medical equipment provider's stock, valued at approximately $735December 9, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Two Sigma Advisers LPTwo Sigma Advisers LP lowered its position in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 26.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 963,900 shares of the medical equipment provider's stock after sellingDecember 9, 2024 | marketbeat.comQuantinno Capital Management LP Cuts Position in NovoCure Limited (NASDAQ:NVCR)Quantinno Capital Management LP cut its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 29.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 251,531 shares of the medical eqDecember 9, 2024 | marketbeat.comHolocene Advisors LP Purchases 22,276 Shares of NovoCure Limited (NASDAQ:NVCR)Holocene Advisors LP lifted its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 42.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,248 shares of the medical equipment provDecember 7, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in NovoCure Limited (NASDAQ:NVCR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 10.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 907,December 7, 2024 | marketbeat.comMetLife Investment Management LLC Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR)MetLife Investment Management LLC increased its holdings in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 129.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,603 shares of the medical equipment providDecember 7, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Gap Up - Time to Buy?NovoCure (NASDAQ:NVCR) Shares Gap Up - Still a Buy?December 6, 2024 | marketbeat.comWhy NovoCure Stock Was Winning Big This WeekDecember 6, 2024 | fool.comBNP Paribas Financial Markets Has $2.75 Million Stock Position in NovoCure Limited (NASDAQ:NVCR)BNP Paribas Financial Markets reduced its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 24.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 175,926 shares of the medical equipment provider's stDecember 6, 2024 | marketbeat.comNovocure Has Already Doubled in 2024. Can It Soar Higher in 2025?December 5, 2024 | fool.comNovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic CancerDecember 4, 2024 | seekingalpha.comPositive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market PotentialDecember 4, 2024 | markets.businessinsider.com115,929 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Edgestream Partners L.P.Edgestream Partners L.P. purchased a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 115,929 shares of the medical equipment provider's stock, valued at approximDecember 4, 2024 | marketbeat.com22,143 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Intech Investment Management LLCIntech Investment Management LLC purchased a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,143 shares of the medical equipmeDecember 4, 2024 | marketbeat.comNovocure seeks approval after pancreatic cancer wearable scores at Phase IIIDecember 4, 2024 | msn.comBridgewater Associates LP Sells 41,898 Shares of NovoCure Limited (NASDAQ:NVCR)Bridgewater Associates LP lowered its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 51.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,383 shares of the medical equipment provider's stock after selling 41,898 shareDecember 3, 2024 | marketbeat.comNovoCure’s PANOVA-3 Trial Success Boosts Oncology ProspectsDecember 3, 2024 | markets.businessinsider.comNovocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment SurgesDecember 2, 2024 | msn.comNovocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFieldsDecember 2, 2024 | seekingalpha.comZai Lab, Novocure Report Positive Topline Results From Phase 3 PANOVA-3 Trial Of TTFields TherapyDecember 2, 2024 | markets.businessinsider.comNovocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerDecember 2, 2024 | stockhouse.comNavigating 5 Analyst Ratings For NovoCureDecember 2, 2024 | benzinga.comNovocure therapy succeeds in pancreatic cancer trialDecember 2, 2024 | msn.comNovocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy SuccessDecember 2, 2024 | finance.yahoo.comNovocure's pancreatic cancer treatment meets main goal in late-stage studyDecember 2, 2024 | reuters.comZai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerDecember 2, 2024 | businesswire.comNovoCure Limited (NASDAQ:NVCR) Stock Position Lifted by Fmr LLCFmr LLC lifted its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 0.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,232,008 shares of the medical equipment provider's stock afterDecember 2, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by PDT Partners LLCPDT Partners LLC lessened its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 40.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 112,083 shares of the medical equipment provider's stock after selling 76December 1, 2024 | marketbeat.comNovocure to Participate in Upcoming Investor ConferencesNovember 27, 2024 | businesswire.comNovoCure Limited (NASDAQ:NVCR) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 16.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 426,263 shares of the medical equipment provider's stock after acquirNovember 23, 2024 | marketbeat.comNovocure secures FDA approval for add-ons to brain cancer treatment wearableNovember 23, 2024 | msn.comFDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for GlioblastomaNovember 22, 2024 | tmcnet.comNovoCure’s Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential RisksNovember 22, 2024 | markets.businessinsider.comFDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for GlioblastomaNovember 21, 2024 | finance.yahoo.comNovocure: FDA Approves HFE Transducer Arrays For Use With Optune Gio - Quick FactsNovember 21, 2024 | markets.businessinsider.comNovocure announces FDA approval of new head flexible electrode transducer arraysNovember 21, 2024 | markets.businessinsider.comNovocure participates in a conference call with JPMorganNovember 16, 2024 | markets.businessinsider.comNovoCure Limited (NASDAQ:NVCR) Given Average Rating of "Moderate Buy" by BrokeragesShares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating toNovember 16, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 1.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,659,314 shares of the medical equipment provider's stock after selling 28,207 shares durNovember 13, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Purchased by Nordwand Advisors LLCNordwand Advisors LLC raised its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 100.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 3,029,824 shares of the medical equipment provider's stock after buying an additional 1,514,824 shares duringNovember 9, 2024 | marketbeat.comInsider Selling: NovoCure Limited (NASDAQ:NVCR) Insider Sells 810 Shares of StockNovember 5, 2024 | insidertrades.comMichal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) StockNovoCure Limited (NASDAQ:NVCR - Get Free Report) insider Michal Nath Puri sold 810 shares of the firm's stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $15.79, for a total transaction of $12,789.90. Following the completion of the transaction, the insider now owns 110,093 shares in the company, valued at $1,738,368.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 4, 2024 | marketbeat.comFY2024 EPS Estimates for NovoCure Increased by HC WainwrightNovoCure Limited (NASDAQ:NVCR - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for NovoCure in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst E. Bodnar now anticipates that the mediNovember 4, 2024 | marketbeat.com Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now NVCR Media Mentions By Week NVCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.730.61▲Average Medical News Sentiment NVCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼35▲NVCR Articles Average Week Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Solventum News Smith & Nephew News Penumbra News Glaukos News Bausch + Lomb News Inspire Medical Systems News PROCEPT BioRobotics News Axonics News Envista News Inari Medical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
